UPCC 30818: A Phase 2 Open-Label Single-Arm Multicenter Study to Assess the Safety and Efficacy of ASP1650 a Monoclonal Antibody Targeting Claudin 6 (CLDN6) in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors

Age
99 years or below
Gender
All
participants needed
10
Location
1

Brief description of study

The goal of this study is to confirm that an investigational study drug, ASP1650, is both safe and effective as a treatment in participants with incurable, refractory germ cell tumors that have Claudin 6 (CLDN6) expression.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Incurable Platinum Refractory Germ Cell Tumors, Tumors
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 832068
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research